PDGFR(血小板衍生生长因子受体)
PDGFR (platelet-derived growth factor receptor) is a group of cell surface tyrosine kinase receptors for members of the PDGF (platelet-derived growth factor) family.
Products for PDGFR
- Cat.No. 产品名称 Information
- GC69619 Olaratumab Olaratumab(IMC-3G3; LY3012207) 是一种抗血小板衍生生长因子受体α (PDGFRα)的人单克隆 IgG1 抗体,具有抗肿瘤活性。
- GC67774 CT52923 CT52923 是一种选择性的血小板衍生生长因子受体 (PDGFR) 拮抗剂,具有口服活性。CT52923 也是一种 ATP 竞争性抑制剂。CT52923 可用于病理疾病的研究,包括动脉粥样硬化、肾小球肾炎、肝硬化、肺纤维化和癌症。
- GC66385 Tovetumab Tovetumab (MEDI-575) 是一种抗 PDGFRα 单克隆抗体,可选择性的阻断 PDGFRα 信号转导。Tovetumab 可用于胶质母细胞瘤和非小细胞肺癌 (NSCLC) 的研究。
- GC65366 PDGFRα kinase inhibitor 1 PDGFRα kinase inhibitor 1 是一种高选择性 II 型 PDGFRα 激酶抑制剂,抑制 PDGFRα 和 PDGFRβ 的 IC50 分别为 132 nM 和 6115 nM。
- GC64340 Zeteletinib Zeteletinib (BOS-172738; DS-5010) 是一种口服有效的,选择性 RET 激酶抑制剂,对 RET 具有纳摩尔效力,对 VEGFR2 具有 >300 倍的选择性。Zeteletinib 对野生型 RET、RETV804M/L gatekeeper 突变体和最常见的致癌 RET 突变体 M918T 显示出较高的效力。Zeteletinib 具有强大的抗肿瘤活性。
- GC49700 Takeda-6d A dual inhibitor of RAF kinases and VEGFR2
- GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib
- GC62453 GZD856 formic GZD856 formic 是一种有效的和具有口服活性的 PDGFRα/β 抑制剂,IC50 值分别为 68.6 和 136.6 nM。GZD856 formic 也是 Bcr-AblT315I 的抑制剂,对天然 Bcr-Abl 和 T315I 突变型的 IC50 值分别为 19.9 和 15.4 nM。GZD856 formic 具有抗肿瘤活性。
- GC62291 (Z)-Orantinib (Z)-Orantinib ((Z)-SU6668) 是一种有效,选择性,具有口服活性和 ATP 竞争性的 Flk‐1/KDR,PDGFRβ 和 FGFR1 抑制剂,IC50 值分别为 2.1,0.008 和 1.2 µM。(Z)-Orantinib 是有效的抗血管生成和抗肿瘤剂,可诱导已建立的肿瘤消退。
- GC62145 Chiauranib Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy.
- GC62114 Seralutinib Seralutinib (PK10571, GB002) is a novel PDGFR kinase inhibitor with IC50s of 8 nM and 10 nM for PDGFRα and PDGFRβ in enzyme assays, respectively.
- GC61957 SU4984 SU4984 是一种蛋白质酪氨酸激酶抑制剂,抑制成纤维细胞生长因子受体 1 (FGFR1) 的 IC50 值为 10-20 µM。SU4984 还可抑制血小板衍生的生长因子受体和胰岛素受体的活性。SU4984 可用于癌症研究。
- GC48118 Sunitinib-d10 An internal standard for the quantification of sunitinib
- GC60930 Imatinib D4 ImatinibD4(STI571D4)是Imatinib(STI571)的氘代物。Imatinib是一种口服生物可用的酪氨酸激酶抑制剂,可选择性抑制BCR/ABL,v-Abl,PDGFR,c-kit激酶活性。
- GC39612 Imatinib D8 Imatinib D8 (STI571 D8) 是 Imatinib (STI571) 的氘代物。Imatinib 是一种口服生物可用的酪氨酸激酶抑制剂,可选择性抑制 BCR/ABL,v-Abl,PDGFR,c-kit 激酶活性。
- GC39314 Tyrphostin AG1433 Tyrphostin AG1433 (AG1433, SU1433) is a selective platelet-derived growth factor receptor β (PDGFRβ) and vascular endothelial growth factor receptor 2 (VEGFR-2, Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively.
-
GC38853
Tandutinib hydrochloride
An antagonist of PDGFRβ, FLT3, and c-
Kit - GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib
- GC38519 Ilorasertib hydrochloride A multi-kinase inhibitor
- GC38380 Vorolanib X-82 (Vorolanib, CM082) is an oral, multikinase, dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with antiangiogenic and antineoplastic activities.
- GC37808 Toceranib phosphate A multi-targeted receptor tyrosine kinase inhibitor
- GC37773 TG 100801 Hydrochloride TG 100801 Hydrochloride 是TG 100572的前药,通过去酯化产生TG 100572,开发用来治疗年龄相关的黄斑变性。TG 100572是多靶点激酶抑制剂,抑制受体酪氨酸激酶 (receptor tyrosine kinases) 和Src激酶 (Src kinases); 对VEGFR1,VEGFR2,FGFR1,FGFR2,PDGFRβ,Fgr,Fyn,Hck,Lck,Lyn,Src,Yes 的 IC50 值分别为2,7,2,16,13,5,0.5,6,0.1,0.4,1,0.2。
- GC37772 TG 100572 Hydrochloride TG 100572 Hydrochloride 是多靶点激酶抑制剂,抑制受体酪氨酸激酶 (receptor tyrosine kinases) 和Src激酶 (Src kinases); 对VEGFR1,VEGFR2,FGFR1,FGFR2,PDGFRβ,Fgr,Fyn,Hck,Lck,Lyn,Src,Yes 的 IC50 值分别为2,7,2,16,13,5,0.5,6,0.1,0.4,1,0.2 nM。
- GC37771 TG 100572 TG 100572是多靶点激酶抑制剂,抑制受体酪氨酸激酶 (receptor tyrosine kinases) 和Src激酶 (Src kinases); 对VEGFR1,VEGFR2,FGFR1,FGFR2,PDGFRβ,Fgr,Fyn,Hck,Lck,Lyn,Src,Yes 的 IC50 值分别为2,7,2,16,13,5,0.5,6,0.1,0.4,1,0.2 nM。
- GC37538 Ripretinib A KIT and PDGFRα inhibitor
-
GC36745
Nintedanib esylate
Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability .
- GC36596 Methylnissolin A flavonoid with antiproliferative activity
- GC36546 Masitinib mesylate An inhibitor of c-Kit
- GC36438 Lenvatinib mesylate An inhibitor of VEGFR2 and VEGFR3
- GC35225 AC710 Mesylate A PDGFR family kinase inhibitor
- GC44583 PD 089828 An inhibitor of EGFR, PDGFβ, FGF, and c-Src
- GC43885 Hypothemycin A resorcylic acid lactone polyketide with diverse biological activities
- GC40567 N-(p-Coumaroyl) Serotonin A natural antioxidant with anti-atherosclerotic actions
- GC34159 Ilorasertib (ABT-348) A multi-kinase inhibitor
- GC34126 NVP-ACC789 (ACC-789) An inhibitor of VEGFRs
- GC34026 Tyrosine kinase-IN-1 Tyrosinekinase-IN-1是多靶点的酪氨酸激酶抑制剂,抑制KDR,Flt-1,FGFR1和PDGFRα的IC50值分别为4,20,4,2nM。
- GC33362 Amuvatinib hydrochloride (MP470 hydrochloride) A multi-targeted RTK inhibitor
- GC33201 GZD856 GZD856是一种新型,有口服活性的PDGFRα/β抑制剂,IC50分别为68.6和136.6nM。具有抗肺癌活性。也是Bcr-AblT315I的抑制剂,对Bcr-Abl和T315I突变型的IC50分别为19.9和15.4 nM。
- GC33004 Cediranib maleate (AZD-2171 maleate) An inhibitor of VEGF receptor tyrosine kinases
- GC32867 Flumatinib (HHGV678) A Bcr-Abl inhibitor
-
GC32835
PP58
PP58是吡啶[2,3-d]嘧啶化合物,抑制PDGFR,FGFR和Src家族活性的IC50值在纳摩尔级。
- GC32458 Trapidil (AR-12008) An inhibitor of PDGF-induced activity and an antiplatelet agent
- GC19074 Avapritinib A dual inhibitor of KIT and PDGFRα mutant kinases
- GC18168 JI-101 An inhibitor of VEGFR2, PDGFRβ, and EphB4
- GC18167 AC710 A PDGFR family kinase inhibitor
- GC16235 AG-1295 A selective inhibitor of PDGF receptor kinase
- GC11712 AG-370 A selective inhibitor of PDGF receptor kinase.
- GC14544 JNJ-10198409 A potent PDGF tyrosine kinase inhibitor
- GC17959 AZD2932 A multi-kinase inhibitor
- GC12686 SU 16f A potent inhibitor of PDGFRβ